obsolete_cystic fibrosis: ['A congenital metabolic disorder affecting the exocrine glands, inherited as an autosomal trait. The secretions of exocrine glands are abnormal, resulting in excessively viscid mucus production which causes obstruction of passageways (including pancreatic and bile ducts, intestines, and bronchi). The sweat sodium and chloride content are increased. Symptoms usually appear in childhood and include meconium ileus, poor growth despite good appetite, malabsorption and foul bulky stools, chronic bronchitis with cough, recurrent pneumonia, bronchiectasis, emphysema, clubbing of the fingers, and salt depletion in hot weather. -- 2003', 'A congenital metabolic disorder affecting the exocrine glands, inherited as an autosomal trait. The secretions of exocrine glands are abnormal, resulting in excessively viscid mucus production which causes obstruction of passageways (including pancreatic and bile ducts, intestines, and bronchi). The sweat sodium and chloride content are increased. Symptoms usually appear in childhood and include meconium ileus, poor growth despite good appetite, malabsorption and foul bulky stools, chronic bronchitis with cough, recurrent pneumonia, bronchiectasis, emphysema, clubbing of the fingers, and salt depletion in hot weather.']
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
58 |
4. Check minimum number of eventsNone |
58 |
5. Include endpointsNone |
58 |
6. Filter based on genotype QC (FinnGen only) |
58 |
Control definitions (FinnGen only)
- Control exclude
- E4_METABOLIA
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Cystic fibrosis, other manifestations/unspecified
based on the number of shared cases.
Similar with more cases:
- Cystic fibrosis
- Metabolic disorders
- Endocrine, nutritional and metabolic diseases
- Any operation in hilmo
- Any event in hilmo or specialist outpatient
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 334 | 163 | 167 |
| Only index persons | 240 | 118 | 122 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.00 | 0.00 | 0.00 |
| Only index persons | 0.00 | 0.00 | 0.00 |
| Median age at first event (years) | |||
| Whole population | 17.26 | 21.54 | 12.15 |
| Only index persons | 16.03 | 20.33 | 11.87 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 58 | 32 | 26 |
| Unadjusted period prevalence (%) | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | 10.35 | 14.91 | 4.73 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
No data
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 54
- Matched controls
- 541
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E84.9
ICD-10 Finland
Cystic fibrosis, unspecified
+∞
49.9
40
*
E84.0
ICD-10 Finland
Cystic fibrosis with pulmonary manifestations
+∞
39.5
33
*
304
Kela drug reimbursment
Dornase alfa
+∞
34.0
29
*
R05CB13
ATC
dornase alfa (desoxyribonuclease); inhalant
+∞
34.0
29
*
A09AA02
ATC
multienzymes (lipase, protease etc.)
560.5
31.2
28
*
J01GB01
ATC
tobramycin; inhalant, parenteral
+∞
30.0
26
*
133
Kela drug reimbursment
Severe chronic pancreatic insufficiency
521.1
29.9
27
*
601
Kela drug reimbursment
Severe malabsorption of nutrients, mainly fats
+∞
27.4
24
*
NK6QA
NOMESCO Finland
Measurement of bone density from tow or more locations with X-ray
85.9
27.2
29
7
E84.1
ICD-10 Finland
Cystic fibrosis with intestinal manifestations
+∞
24.9
22
*
E84.8
ICD-10 Finland
Cystic fibrosis with other manifestations
+∞
23.7
21
*
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
48.4
19.5
23
8
2770A
ICD-9 Finland
Other and unspecified disorders of metabolism, Cystic fibrosis
+∞
18.8
17
*
J32.0
ICD-10 Finland
Chronic maxillary sinusitis
34.6
18.6
24
12
J01XB01
ATC
colistin; inhalant, parenteral
+∞
17.6
16
*
J18.9
ICD-10 Finland
Pneumonia, unspecified
15.5
17.5
34
53
L04AA06
ATC
mycophenolic acid; systemic
120.8
16.7
17
*
UGC12
NOMESCO Finland
Flexible bronchoscopy
25.5
15.7
22
14
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
40.6
15.6
19
7
E13.9
ICD-10 Finland
Other specified diabetes mellitus, without complications
110.8
15.5
16
*
127
Kela drug reimbursment
Transplant complication
110.8
15.5
16
*
Z94.2
ICD-10 Finland
Lung transplant status
+∞
15.3
14
*
J32.4
ICD-10 Finland
Chronic pansinusitis
202.6
15.3
15
*
UDH02
NOMESCO Finland
Rhinopharyngoscopy
20.9
14.6
22
17
L04AD02
ATC
tacrolimus; systemic (calcineurin inhibitors)
+∞
14.2
13
*
GD1CD
NOMESCO Finland
Thorax extensive CT-examination
+∞
14.2
13
*
TDM10
NOMESCO Finland
Puncture of maxillary antrum
32.7
14.0
18
8
DMB20
NOMESCO Finland
Functional endoscopic opening of maxillary antrum
32.7
14.0
18
8
XG410
NOMESCO Finland
Flow-volume spirometry
32.7
14.0
18
8
GD1AA
NOMESCO Finland
Thorax X-ray examination
10.4
13.9
40
116
J01MA12
ATC
levofloxacin; systemic
12.7
13.7
27
39
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
34.4
13.5
17
7
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
18.2
13.3
21
18
XG412
NOMESCO Finland
Flow-volume spirometry with bronchospasmolysis
21.7
13.0
19
13
TGD04
NOMESCO Finland
Needle biopsy of the lungs in bronchoscopy
+∞
13.0
12
*
GDG10
NOMESCO Finland
Bilateral transplantation of lung
+∞
13.0
12
*
J33.0
ICD-10 Finland
Polyp of nasal cavity
50.6
13.0
15
*
TGC00
NOMESCO Finland
Bronchial lavation
40.4
12.4
15
5
R4110
NOMESCO Finland
Physiotherapy
9.3
12.4
32
73
203
Kela drug reimbursment
Chronic asthma and similar chronic obstructive pulmonary diseases
9.4
12.2
30
63
GD1BT
NOMESCO Finland
Biopsy of lung with X-ray guidance
+∞
11.9
11
*
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
16.5
11.7
19
17
R4190
NOMESCO Finland
Nutritional therapy
18.6
11.7
18
14
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
18.6
11.7
18
14
602
Kela drug reimbursment
Children's severe malnutrition
55.7
11.5
13
*
J15.9
ICD-10 Finland
Bacterial pneumonia, unspecified
16.2
11.1
18
16
E84
ICD-10 Finland
Cystic fibrosis
+∞
10.8
10
*
J01CF05
ATC
flucloxacillin; systemic
22.4
10.6
15
9
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
7.7
10.6
30
75
Z71.3
ICD-10 Finland
Dietary counselling and surveillance
18.3
10.5
16
12
FXA00
NOMESCO Finland
Total cardiopulmonary bypass in normothermia or moderate hypothermia at concurrent surgical procedure
50.2
10.5
12
*
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
7.7
10.2
28
66
GD1AD
NOMESCO Finland
Thorax CT examination
27.8
9.9
13
6
DNB20
NOMESCO Finland
Endoscopic ethmoidectomy
37.7
9.9
12
*
R04.2
ICD-10 Finland
Haemoptysis
120.2
9.8
10
*
J01MA02
ATC
ciprofloxacin; systemic
6.6
9.7
34
110
XX4BW
NOMESCO Finland
NA
+∞
9.7
9
*
27300
ICD-8 Finland
Other and unspecified congenital disorders of metabolism, Cystic fibrosis (mucoviscidosis)
+∞
9.7
9
*
R07AX32
ATC
ivacaftor, tezacaftor and elexacaftor; oral
+∞
9.7
9
*
3045
Kela drug reimbursment
NA
+∞
9.7
9
*
R07AX02
ATC
ivacaftor; oral
+∞
9.7
9
*
A10AB05
ATC
insulin aspart; parenteral (insulins and analog. for injection, fast-acting)
16.7
9.6
15
12
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
30.1
9.4
12
5
ZX120
NOMESCO Finland
Intravenous
12.8
9.1
16
17
J20.9
ICD-10 Finland
Acute bronchitis, unspecified
8.1
9.0
22
42
J84.1
ICD-10 Finland
Other interstitial pulmonary diseases with fibrosis
60.1
9.0
10
*
J01MA14
ATC
moxifloxacin; systemic
11.4
8.6
16
19
TFB00
NOMESCO Finland
Cathetrisation of pulmonal artery
+∞
8.5
8
*
B05XA03
ATC
sodium chloride; parenteral
+∞
8.5
8
*
DPA25
NOMESCO Finland
Trephine of frontal sinus through nose
+∞
8.5
8
*
R05CB02
ATC
bromhexine; systemic
+∞
8.5
8
*
RS123
NOMESCO Finland
NA
+∞
8.5
8
*
R03BA05
ATC
fluticasone; inhalant
6.9
8.5
24
56
WX872
NOMESCO Finland
Intensive care
21.5
8.5
12
7
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
12.5
8.5
15
16
WX302
NOMESCO Finland
Thoracal epidural anesthesy
18.8
8.2
12
8
WX404
NOMESCO Finland
Intravenous generell anesthesy
6.5
8.2
24
59
Z3226
NOMESCO Finland
Physiotherapist
6.6
8.1
23
54
UDM02
NOMESCO Finland
Sinoscopy
22.5
8.0
11
6
A05AA02
ATC
ursodeoxycholic acid; oral
22.5
8.0
11
6
DM1AI
NOMESCO Finland
Cone beam CT of paranasal sinus
30.0
7.9
10
*
Z31.5
ICD-10 Finland
Genetic counselling
12.1
7.9
14
15
R03AC02
ATC
salbutamol; inhalant
5.7
7.8
41
192
TPX10
NOMESCO Finland
Implantation of vascular injection port
15.0
7.5
12
10
R03AK06
ATC
salmeterol and fluticasone; inhalant
7.1
7.4
19
38
Z3229
NOMESCO Finland
Other healthcare associate professional
9.0
7.1
15
22
ZXA10
NOMESCO Finland
Bilateral
6.1
7.1
21
51
DM1AD
NOMESCO Finland
CT of paranasal sinuses and face area
20.0
7.0
10
6
R03BA02
ATC
budesonide; inhalant
5.8
7.0
22
57
4730A
ICD-9 Finland
Chronic sinusitis, Maxillary
46.0
7.0
8
*
GD1BD
NOMESCO Finland
Thorax extensive CT-examination
26.4
6.9
9
*
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
7.6
6.8
16
28
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
10.3
6.8
13
16
FM1BE
NOMESCO Finland
Cardiac ultrasound examination through oesophagus
17.1
6.7
10
7
ZXE50
NOMESCO Finland
More than nine and less than 12 hours
78.8
6.6
7
*
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
7.1
6.5
16
30
WX408
NOMESCO Finland
General anesthesy, balanced
4.8
6.5
26
88
A02BA03
ATC
famotidine; systemic
30.7
6.4
8
*
K90.3
ICD-10 Finland
Pancreatic steatorrhoea
+∞
6.4
6
*
V07AB
ATC
Solvents and diluting agents, incl. irrigating solutions
+∞
6.4
6
*
J02AC04
ATC
posaconazole; systemic
+∞
6.4
6
*
DPA30
NOMESCO Finland
Sphenotomy
+∞
6.4
6
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
5.9
6.2
18
42
TPH04
NOMESCO Finland
Cathetrisation of vein
5.0
6.2
22
65
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
unit
cases
controls
-log10(p)
N cases
N controls
(3016407) Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay
30
10
61.07
48.15
5.5
1.8
g/l
3.4
3.4
—
30
10
(3042194) Human metapneumovirus RNA [Presence] in Specimen by NAA with probe detection
23
10
37.46
33.11
5.2
1.5
—
—
—
0
0
(3040853) Adenovirus DNA [Identifier] in Specimen by NAA with probe detection
23
10
37.46
33.11
4.5
1.5
—
—
—
0
0
(3000494) Fungus identified in Specimen by Culture
36
41
21.51
32.70
14.0
1.3
—
—
—
0
0
(4010399)
27
24
20.18
27.91
3.7
1.2
—
—
—
0
0
(43055120) Cytomegalovirus DNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection
21
11
29.36
27.90
25.0
5.0
iu/ml
107.4
—
—
5
0
(3019250) Coagulation factor VIII activity actual/normal in Platelet poor plasma by Coagulation assay
28
8
65.37
25.02
6.3
3.1
%
155.9
145.8
—
28
8
(3014162) Mycobacterium tuberculosis DNA [Presence] in Specimen by NAA with probe detection
24
7
56.61
20.97
7.0
2.0
—
—
—
0
0
(3044938) Influenza virus A RNA [Presence] in Specimen by NAA with probe detection
33
62
11.03
19.57
5.3
2.0
—
—
—
0
0
(3038288) Influenza virus B RNA [Presence] in Specimen by NAA with probe detection
28
45
11.10
18.75
4.5
1.7
—
—
—
0
0
(3043924) Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection
28
45
11.10
18.75
4.1
1.7
—
—
—
0
0
(3005702) Mycobacterium sp identified in Specimen by Organism specific culture
22
7
49.20
18.73
5.2
1.1
—
—
—
0
0
(3000492) Spirometry study
26
42
10.41
17.18
4.1
1.3
—
—
—
0
0
(3022948) Iron [Moles/volume] in Serum or Plasma
31
62
9.59
17.11
4.6
2.1
umol/l
12.1
13.3
0.40
31
57
(3030692) Respiratory virus DNA+RNA [Identifier] in Specimen by NAA with probe detection
20
6
49.43
17.11
4.1
1.2
—
—
—
0
0
(40765161) Human bocavirus DNA [Presence] in Specimen by NAA with probe detection
20
8
37.04
16.03
4.4
1.5
—
—
—
0
0
(3042936) Bacteria identified in Isolate by Culture
29
60
8.67
15.30
5.6
2.3
—
—
—
0
0
(3035509) Tobramycin [Mass/volume] in Serum or Plasma
14
0
+∞
15.26
6.5
0.0
mg/l
0.7
—
—
9
0
(3002482) Mycoplasma pneumoniae DNA [Presence] in Specimen by NAA with probe detection
19
8
34.31
14.98
5.0
1.3
—
—
—
0
0
(3037692) Legionella sp identified in Specimen by Organism specific culture
13
0
+∞
14.12
4.5
0.0
—
—
—
0
0
(3018418) pH of Serum or Plasma
36
101
7.76
13.96
11.7
3.3
ph
7.4
7.4
1.03
14
23
(3016431) Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
47
173
10.05
13.79
24.0
4.4
mmol/l
1.2
1.2
1.15
36
140
(3051714) Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma
36
104
7.49
13.45
4.9
1.6
mg/l
1.5
0.9
0.32
24
68
(3031478) Chlamydophila pneumoniae DNA [Presence] in Specimen by NAA with probe detection
17
7
33.45
13.40
5.0
1.3
—
—
—
0
0
(3042596) Human coronavirus RNA [Presence] in Specimen by NAA with probe detection
17
8
29.23
12.93
4.4
1.3
—
—
—
0
0
(3007853) Bacteria identified in Skin by Aerobe culture
23
44
8.01
12.77
4.1
1.3
—
—
—
0
0
(3017181) Myelocytes/100 leukocytes in Blood
20
36
7.95
11.63
8.9
4.6
%
0.8
0.7
—
8
13
(3013721) Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
39
139
6.51
11.14
10.1
2.2
u/l
27.0
28.4
0.26
39
127
(3025159) Blasts/100 leukocytes in Blood
19
34
7.82
11.06
8.9
4.7
%
0.0
0.1
—
6
10
(3021440) Promyelocytes/100 leukocytes in Blood
19
35
7.59
10.75
9.3
4.6
%
0.0
0.1
—
7
11
(3002179) Metamyelocytes/100 leukocytes in Blood
19
35
7.59
10.75
8.6
4.6
%
0.8
0.3
—
6
9
(3023368) Bacteria identified in Blood by Culture
30
88
5.99
10.56
9.3
4.8
—
—
—
0
0
(42870588) Differential panel, method unspecified - Blood
40
154
6.15
10.23
30.0
5.7
—
—
—
0
0
(3016881) Enterovirus RNA [Presence] in Specimen by NAA with probe detection
13
6
27.27
9.86
2.8
1.5
—
—
—
0
0
(40757373) Influenza virus identified in Isolate
9
0
+∞
9.63
3.9
0.0
—
—
—
0
0
(3007164) IgA [Mass/volume] in Serum or Plasma
34
120
5.43
9.46
2.7
1.7
g/l
2.7
2.7
0.01
26
63
(3015399) Transferrin receptor.soluble [Mass/volume] in Serum or Plasma
32
111
5.20
9.00
3.6
1.9
mg/l
2.8
2.7
0.13
32
91
(3012516) Albumin [Mass/volume] in Urine
27
82
5.29
8.89
4.3
3.2
mg/l
164.3
101.8
0.24
22
49
(40769539) Bacteria identified based on 16S rRNA gene [Identifier] in Specimen by Sequencing
12
7
21.10
8.49
3.8
1.9
—
—
—
0
0
(3051552) Clostridioides difficile toxin genes [Presence] in Stool by NAA with probe detection
14
24
7.37
8.30
3.9
1.6
—
—
—
0
0
(3021589) Normoblasts [#/volume] in Blood
45
222
5.58
7.79
29.8
7.5
e9/l
0.0
0.0
0.00
39
178
(3042733) HLA Ab [Presence] in Serum
7
0
+∞
7.44
2.4
0.0
—
—
—
0
0
(3020565) Legionella pneumophila DNA [Presence] in Specimen by NAA with probe detection
10
5
23.66
7.42
3.2
1.2
—
—
—
0
0
(40758558) Short blood count panel - Blood
31
119
4.45
7.36
20.8
4.5
—
—
—
0
0
(3030366) Cystatin C [Mass/volume] in Serum or Plasma
10
13
9.09
7.36
5.8
7.2
mg/l
1.6
1.2
—
10
13
(3012477) Bordetella pertussis DNA [Presence] in Specimen by NAA with probe detection
10
6
19.70
7.02
3.3
1.2
—
—
—
0
0
(4306422)
10
6
19.70
7.02
1.2
1.3
—
—
—
0
0
(3032080) INR in Blood by Coagulation assay
32
133
4.14
6.68
7.3
7.8
inr
1.1
1.2
0.52
14
48
(3021952) Alkaline phosphatase isoenzymes [Enzymatic activity/volume] in Serum or Plasma by Heat stability
9
5
20.88
6.49
2.1
1.0
—
—
—
0
0
(3016273) Islet cell 512 Ab [Units/volume] in Serum
6
0
+∞
6.35
1.0
0.0
—
—
—
0
0
(3027653) Mycophenolate [Mass/volume] in Serum or Plasma
6
0
+∞
6.35
4.8
0.0
mg/l
2.0
—
—
6
0
(3020287) Protein C actual/normal in Platelet poor plasma by Coagulation assay
9
6
17.38
6.12
1.3
1.5
%
95.0
128.3
—
9
6
(3019050) Tissue transglutaminase IgA Ab [Units/volume] in Serum
31
135
3.78
5.88
1.6
1.5
u/ml
0.5
1.4
—
5
20
(3003396) Base excess in Arterial blood by calculation
13
30
5.30
5.63
10.2
4.1
mmol/l
0.5
1.0
—
8
24
(3020629) Protein S Free Ag actual/normal in Platelet poor plasma by Immunoassay
8
5
18.20
5.58
1.1
1.4
%
73.6
117.6
—
8
5
(3007844) Epstein Barr virus capsid IgM Ab [Units/volume] in Serum by Immunoassay
10
18
6.50
5.53
1.2
1.2
—
—
—
0
0
(3012544) pH of Venous blood
14
36
4.81
5.35
9.7
3.6
—
—
—
0
0
(36659890) Mycobacterial identification panel - Specimen by Molecular genetics method
5
0
+∞
5.28
7.0
0.0
—
—
—
0
0
(36031861) Influenza virus A and B and SARS-CoV-2 (COVID-19) and Respiratory syncytial virus RNA panel - Respiratory system specimen by NAA with probe detection
11
23
5.67
5.26
1.9
2.0
—
—
—
0
0
(3027529) Toxoplasma gondii IgM Ab [Units/volume] in Serum
8
6
15.16
5.24
1.1
1.5
—
—
—
0
0
(3014959) Toxoplasma gondii IgG Ab [Units/volume] in Serum
8
6
15.16
5.24
2.3
3.2
—
—
—
0
0
(3000991) Gas panel - Venous blood
12
30
4.78
4.70
17.7
4.8
—
—
—
0
0
(3015816) F5 gene p.Arg506Gln [Presence] in Blood or Tissue by Molecular genetics method
8
8
11.34
4.68
1.1
1.3
—
—
—
0
0
(3029287) Urinalysis microscopic panel [#/volume] - Urine by Automated count
32
161
3.20
4.54
9.2
3.2
—
—
—
0
0
(3029879) Epithelial cells.squamous [#/volume] in Urine by Automated count
20
76
3.49
4.48
6.3
2.7
e6/l
1.7
1.3
0.15
15
41
(36305247) Microscopic observation [Identifier] in Isolate by Gram stain
8
9
10.07
4.43
5.3
1.4
—
—
—
0
0
(36304419) Bacteria [Presence] in Urine
27
131
2.99
3.97
7.4
2.8
—
—
—
0
0
(3015635) Cytomegalovirus IgM Ab [Units/volume] in Serum or Plasma
9
16
6.44
3.83
1.4
1.1
—
—
—
0
0
(3017918) Cytomegalovirus IgG Ab [Titer] in Serum or Plasma
9
16
6.44
3.83
1.4
1.1
—
—
—
0
0
(3030905) Polymorphonuclear cells [#/volume] in Blood
8
12
7.53
3.81
8.0
4.7
e9/l
5.7
3.6
—
8
12
(3032035) Polymorphonuclear cells/100 leukocytes in Blood
8
13
6.94
3.64
8.0
5.0
%
61.5
51.2
—
8
13
(3048773) Triglyceride [Moles/volume] in Serum or Plasma --fasting
52
395
4.05
3.36
5.9
3.2
mmol/l
1.3
1.2
0.34
46
358
(3012220) Varicella zoster virus IgM Ab [Presence] in Serum by Immunoassay
7
11
7.06
3.29
1.1
1.3
—
—
—
0
0
(3014148) Varicella zoster virus Ab [Titer] in Serum
7
11
7.06
3.29
1.1
1.4
—
—
—
0
0
(3023602) Cholesterol in HDL [Moles/volume] in Serum or Plasma
53
412
4.31
3.28
6.6
3.5
mmol/l
1.5
1.4
0.05
48
374
(3019900) Cholesterol [Moles/volume] in Serum or Plasma
53
416
4.17
3.07
6.9
3.5
mmol/l
4.1
4.6
2.87
48
379
(43054914) Glucose tolerance 2 hours panel - Serum or Plasma
14
53
3.16
3.06
1.8
1.9
—
—
—
0
0
(40768804) Tissue Pathology biopsy report
29
163
2.56
3.04
3.7
1.9
—
—
—
0
0
(3012202) Varicella zoster virus DNA [Presence] in Specimen by NAA with probe detection
5
5
10.76
3.03
2.2
1.4
—
—
—
0
0
(3048929) Epstein Barr virus Ab [Presence] in Serum
11
36
3.54
2.99
1.3
1.3
—
—
—
0
0
(3052851) Hemolysis interference index of Serum or Plasma
7
13
5.96
2.96
1.7
2.0
—
—
—
0
0
(4268621)
6
9
7.28
2.94
2.3
2.3
—
—
—
0
0
(3020961) Endomysium IgA Ab [Titer] in Serum
10
31
3.69
2.93
1.4
1.2
—
—
—
0
0
(43054903) Holo-transcobalamin II [Moles/volume] in Serum
25
133
2.55
2.91
2.0
1.5
pmol/l
88.3
101.6
0.83
13
58
(3019060) Gas panel - Arterial blood
8
18
4.97
2.91
2.0
2.5
—
—
—
0
0
(3016293) Bicarbonate [Moles/volume] in Serum or Plasma
8
18
4.97
2.91
15.4
4.3
mmol/l
25.8
25.3
—
8
18
(3001308) Cholesterol in LDL [Moles/volume] in Serum or Plasma
53
421
4.00
2.87
6.8
3.8
mmol/l
2.2
2.8
5.26
48
380
(4035726)
10
32
3.57
2.79
1.9
1.5
—
—
—
0
0
(3025941) Bacteria identified in Stool by Culture
8
19
4.70
2.79
1.0
1.3
—
—
—
0
0
(40760892) CBC W Ordered Manual Differential panel - Blood
23
120
2.52
2.77
18.9
4.8
—
—
—
0
0
(3008486) Thyroxine (T4) free [Moles/volume] in Serum or Plasma
47
344
2.93
2.71
5.9
3.7
pmol/l
14.2
14.5
0.34
41
304
(3022313) Gas panel - Capillary blood
8
20
4.46
2.68
11.8
2.6
—
—
—
0
0
(40762366) Oxygen capacity [Volume Fraction] in Arterial blood
6
11
5.94
2.61
14.8
2.8
—
—
—
0
0
(1616796) Gas panel - Central venous blood
5
7
7.67
2.60
2.8
1.6
—
—
—
0
0
(586526) SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with probe detection
8
21
4.24
2.57
2.8
1.3
—
—
—
0
0
(40764999) Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)
52
417
3.38
2.57
33.7
9.6
ml/min/173m2
89.2
93.7
0.43
46
315
(3037467) Urinalysis macro (dipstick) panel - Urine
42
295
2.54
2.56
9.0
3.9
—
—
—
0
0
(3005785) Creatine kinase.MB [Mass/volume] in Serum or Plasma
9
28
3.61
2.43
2.1
2.8
ug/l
13.7
8.7
—
9
23
(3028369) Herpes simplex virus 1+2 DNA [Presence] in Specimen by NAA with probe detection
5
8
6.70
2.42
2.4
1.3
—
—
—
0
0
(3019800) Troponin T.cardiac [Mass/volume] in Serum or Plasma
24
135
2.33
2.40
2.9
3.3
ng/l
47.5
50.9
0.03
17
78
(3024891) Influenza virus A+B Ag [Presence] in Specimen
6
13
5.01
2.33
1.0
1.1
—
—
—
0
0
(3022145) Colonoscopy Study observation
11
43
2.92
2.25
1.0
1.5
—
—
—
0
0
(46236098) ABO and Rh group [Type] in Blood by Confirmatory method
18
92
2.39
2.20
4.6
2.0
—
—
—
0
0
(3021601) Nitrite [Presence] in Urine by Test strip
33
218
2.19
2.20
6.7
4.5
estimate
0.0
0.0
0.00
12
45
(3035350) Ketones [Presence] in Urine by Test strip
33
219
2.18
2.16
4.3
3.4
estimate
0.0
0.0
—
10
47
(3009201) Thyrotropin [Units/volume] in Serum or Plasma
51
415
2.89
2.11
7.5
4.2
mu/l
2.0
1.8
0.37
45
372
(3010566) Parathyrin.intact [Moles/volume] in Serum or Plasma
5
10
5.35
2.11
5.0
1.9
—
—
—
0
0
(3044640) Blood type and Crossmatch panel - Blood
22
125
2.22
2.11
5.0
2.1
—
—
—
0
0
(3009261) Glucose [Presence] in Urine by Test strip
33
222
2.13
2.06
4.3
3.4
estimate
0.0
0.0
0.00
11
46
(3030306) Epithelial cells.non-squamous [#/volume] in Urine by Automated count
16
80
2.38
2.04
5.4
2.7
e6/l
0.2
0.6
1.07
11
44
(3046279) Procalcitonin [Mass/volume] in Serum or Plasma
5
11
4.86
1.98
4.2
1.9
ug/l
0.6
0.7
—
5
11
(3043362) Influenza virus B Ag [Presence] in Nasopharynx by Immunoassay
5
11
4.86
1.98
1.6
1.1
—
—
—
0
0
(3046524) Influenza virus A Ag [Presence] in Nasopharynx by Immunoassay
5
11
4.86
1.98
1.6
1.1
—
—
—
0
0
(3041096) Erythrocytes [Presence] in Urine by Automated
22
128
2.16
1.97
4.0
2.9
—
—
—
0
0
(3044889) 12 lead EKG panel
37
271
2.01
1.72
10.1
3.2
—
—
—
0
0
(3017766) Complement C4 [Mass/volume] in Serum or Plasma
6
19
3.40
1.71
2.3
1.8
g/l
0.2
0.2
—
6
19
(3000620) Complement C3 [Mass/volume] in Serum or Plasma
6
19
3.40
1.71
2.3
1.8
g/l
0.9
1.2
—
6
19
(3011397) Hemoglobin [Presence] in Urine by Test strip
18
102
2.11
1.69
3.0
3.3
—
—
—
0
0
(40768797) Stomach Pathology biopsy report
10
44
2.54
1.64
1.1
1.2
—
—
—
0
0
(3019309) Folate [Moles/volume] in Red Blood Cells
13
66
2.25
1.58
1.7
1.6
nmol/l
1052.6
1282.8
—
8
44
(3002434) Lupus erythematosus deoxynucleoproteins IgG Ab [Units/volume] in Serum by Immunoassay
5
16
3.32
1.47
1.8
2.9
—
—
—
0
0
(3024135) Streptococcus.beta-hemolytic [Presence] in Throat by Organism specific culture
7
145
0.41
1.47
1.6
1.7
—
—
—
0
0
(40763086) Leukocyte esterase [Presence] in Urine by Automated test strip
25
170
1.83
1.37
3.8
3.4
—
—
—
0
0
(3029937) Albumin [Presence] in Urine by Test strip
19
119
1.89
1.33
3.4
3.9
estimate
0.0
0.0
—
9
45
(40761536) Microorganisms panel - Urine sediment
10
49
2.26
1.31
3.4
3.4
—
—
—
0
0
(3020460) C reactive protein [Mass/volume] in Serum or Plasma
53
469
2.51
1.31
57.2
10.7
mg/l
16.8
20.9
0.81
48
344
(3016251) Hemoglobin.gastrointestinal [Presence] in Stool
5
19
2.78
1.24
3.8
1.8
—
—
—
0
0
(3009542) Hematocrit [Volume Fraction] of Blood
52
456
2.35
1.23
39.8
10.5
%
38.1
40.5
1.38
44
351
(3019902) Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture
8
40
2.16
1.17
3.9
3.6
—
—
—
0
0
(3019225) pH of Specimen
7
31
2.43
1.15
10.6
3.5
—
—
—
0
0
(3022250) Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction
10
54
2.03
1.04
3.9
3.8
u/l
272.2
222.3
—
10
49
(3018251) Fasting glucose [Moles/volume] in Serum or Plasma
48
415
1.91
1.02
6.2
3.4
mmol/l
6.1
5.7
1.23
43
372
(46235831) Pregnancy associated plasma protein A [Multiple of the median] adjusted in Serum or Plasma
0
29
0.00
1.01
0.0
1.5
—
—
—
0
0
(3043238) Trisomy 21 risk [Likelihood] in Fetus
0
29
0.00
1.01
0.0
1.5
—
—
—
0
0
(3049207) Fetal Trisomy 21 risk [Likelihood] Based on maternal age
0
29
0.00
1.01
0.0
1.5
—
—
—
0
0
(3008714) Choriogonadotropin [Multiple of the median] adjusted in Serum or Plasma
0
29
0.00
1.01
0.0
1.5
—
—
—
0
0
(40763531) Fetal Nuchal fold [Multiple of the median] Thickness adjusted for maternal weight
0
29
0.00
1.01
0.0
1.5
—
—
—
0
0
(3003191) Choriogonadotropin (pregnancy test) [Presence] in Serum or Plasma
0
30
0.00
1.00
0.0
1.7
—
—
—
0
0
(3019145) Choriogonadotropin.beta subunit free [Mass/volume] in Serum or Plasma
0
32
0.00
0.98
0.0
1.6
—
—
—
0
0
(3001079) Blood group antibody screen [Presence] in Serum or Plasma
28
213
1.61
0.95
6.6
3.7
—
—
—
0
0
(3021879) Hepatitis B virus core Ab [Presence] in Serum
11
66
1.82
0.86
2.1
1.6
—
—
—
0
0
(3002256) Pathology report gross observation
8
47
1.81
0.85
1.4
1.3
—
—
—
0
0
(3047352) Trisomy 18 risk [Likelihood] in Fetus
0
27
0.00
0.79
0.0
1.5
—
—
—
0
0
(3005033) Fetal Nuchal fold Thickness US
0
27
0.00
0.79
0.0
1.5
—
—
—
0
0
(21492888) Glucose tolerance 2 hours gestational panel - Serum or Plasma
0
27
0.00
0.79
0.0
1.7
—
—
—
0
0
(36660697) Celiac disease serology panel - Serum
9
55
1.75
0.78
1.7
1.1
—
—
—
0
0
(46237023) Hepatitis B virus core and surface Ab and surface Ag panel - Serum
5
26
2.01
0.72
2.0
1.1
—
—
—
0
0
(3015736) pH of Urine
23
177
1.50
0.70
3.7
3.3
—
—
—
0
0
(3013512) EKG study
16
114
1.56
0.68
5.5
2.7
—
—
—
0
0
(40761535) Cells panel - Urine sediment
5
30
1.73
0.63
3.4
3.9
—
—
—
0
0
(3027944) Amphetamines [Presence] in Urine
7
45
1.63
0.51
1.0
2.3
—
—
—
0
0
(43534045) MCM6 gene c.-13910C>T and -13915T>G [Identifier] in Blood or Tissue by Molecular genetics method Nominal
7
45
1.63
0.51
1.0
1.0
—
—
—
0
0
(3028300) Cannabinoids [Presence] in Urine
7
46
1.59
0.50
1.0
2.3
—
—
—
0
0
(3000764) Benzodiazepines [Presence] in Urine
7
46
1.59
0.50
1.0
2.3
—
—
—
0
0
(3027008) Opiates [Presence] in Urine
7
46
1.59
0.50
1.0
2.2
—
—
—
0
0
(3019284) Hepatitis B virus surface Ag [Presence] in Serum
18
140
1.41
0.50
2.1
1.8
—
—
—
0
0
(46235355) HIV 1 and 2 tests - Meaningful Use set
21
172
1.35
0.43
2.1
2.3
—
—
—
0
0
(1001926) Buprenorphine [Presence] in Urine by Screen method
5
33
1.56
0.42
1.0
2.6
—
—
—
0
0
(3000924) Streptococcus pyogenes [Presence] in Throat by Organism specific culture
0
16
0.00
0.42
0.0
1.4
—
—
—
0
0
(3001019) Free T4 and TSH panel - Serum or Plasma
0
17
0.00
0.41
0.0
1.6
—
—
—
0
0
(3004248) Sex hormone binding globulin [Moles/volume] in Serum or Plasma
0
17
0.00
0.41
0.0
1.2
—
42.6
—
0
17
(3016879) Cocaine [Presence] in Urine
6
43
1.44
0.36
1.0
2.3
—
—
—
0
0
(3017143) Hepatitis C virus Ab [Presence] in Serum
13
102
1.35
0.33
2.5
1.6
—
—
—
0
0
(3003694) ABO and Rh group [Type] in Blood
19
160
1.28
0.31
1.4
1.7
—
—
—
0
0
(3024950) Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection
10
123
0.77
0.23
1.5
2.9
—
—
—
0
0
(3004716) Salmonella sp identified in Stool by Organism specific culture
5
41
1.24
0.22
1.2
1.3
—
—
—
0
0
(3026008) Bacteria identified in Urine by Culture
16
137
1.23
0.22
2.8
2.5
—
—
—
0
0
(3047007) Chlamydophila sp Ab [Presence] in Serum
0
11
0.00
0.21
0.0
1.3
—
—
—
0
0
(3049717) Cytology report of Urine Cyto stain
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
(44816844) Macroprolactin [Units/volume] in Serum or Plasma
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
(3042206) Streptococcus agalactiae Ag [Presence] in Vaginal fluid
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
(4034850)
0
12
0.00
0.21
0.0
5.0
—
—
—
0
0
(3000855) Microscopic observation [Identifier] in Vaginal fluid by Gram stain
0
13
0.00
0.21
0.0
1.5
—
—
—
0
0
(3014051) Protein [Presence] in Urine by Test strip
0
13
0.00
0.21
0.0
1.6
—
—
—
0
0
(1761868) Lipid panel - Serum or Plasma
17
149
1.20
0.18
3.7
2.2
—
—
—
0
0
(3019832) Treponema pallidum Ab [Presence] in Serum
12
110
1.11
0.05
1.2
1.9
—
—
—
0
0
(3018006) Microscopic observation [Identifier] in Cervix by Cyto stain.thin prep
10
91
1.12
0.04
1.6
1.3
—
—
—
0
0
(706163) SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection
39
397
0.95
0.01
4.3
3.5
—
—
—
0
0
(3003510) Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection
11
113
0.97
0.00
1.5
2.6
—
—
—
0
0
(40768795) Lymph node Pathology biopsy report
0
6
0.00
0.00
0.0
1.8
—
—
—
0
0
(3041354) Potassium [Moles/volume] in Venous blood
0
6
0.00
0.00
0.0
3.0
—
3.8
—
0
6
(3019497) Choriogonadotropin.beta subunit free [Moles/volume] in Serum or Plasma
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
(3026179) Normetanephrine [Moles/volume] in Serum or Plasma
0
6
0.00
0.00
0.0
2.3
—
0.4
—
0
6
(3018301) Testosterone Free [Moles/volume] in Serum or Plasma
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
(3011166) Borrelia burgdorferi Ab [Presence] in Cerebral spinal fluid
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
(36032269) Testosterone Free [Moles/volume] in Serum or Plasma by calculation
0
6
0.00
0.00
0.0
1.0
—
326.5
—
0
6
(3021788) Differential panel - Synovial fluid
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
(3004915) Chlamydophila pneumoniae IgA Ab [Units/volume] in Serum
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
(3035285) Chloride [Moles/volume] in Venous blood
0
6
0.00
0.00
0.0
3.0
—
106.0
—
0
6
(3009466) Valproate [Moles/volume] in Serum or Plasma
0
8
0.00
0.00
0.0
3.5
—
397.9
—
0
8
(3006093) Chlamydia trachomatis DNA [Presence] in Specimen by NAA with probe detection
7
77
0.90
0.00
1.7
2.1
—
—
—
0
0
(3033705) Calcium.ionized [Moles/volume] in Venous blood
0
5
0.00
0.00
0.0
3.4
—
—
—
0
0
(3045783) Sodium and Potassium panel [Moles/volume] - Serum or Plasma
5
52
0.96
0.00
19.8
4.9
—
—
—
0
0
(3043109) Cytology report of Tissue fine needle aspirate Cyto stain
0
9
0.00
0.00
0.0
1.4
—
—
—
0
0
(3028531) Enolase.neuron specific [Mass/volume] in Serum or Plasma
0
7
0.00
0.00
0.0
1.4
—
16.7
—
0
7
(3050238) Crystals [Presence] in Synovial fluid by Light microscopy
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
(3039443) Prostate specific Ag panel - Serum or Plasma
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
(3023420) DNA double strand Ab [Units/volume] in Serum
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
(3022806) Fractional oxyhemoglobin in Capillary blood
0
5
0.00
0.00
0.0
1.4
—
89.7
—
0
5
(21494670) JAK2 gene exon 14 targeted mutation analysis in Blood or Tissue by Molecular genetics method
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
(3032155) Metanephrine Free [Moles/volume] in Serum or Plasma
0
5
0.00
0.00
0.0
2.4
—
—
—
0
0
(3010380) Borrelia burgdorferi IgG Ab [Units/volume] in Cerebral spinal fluid
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
(3002148) Methylenedioxymethamphetamine [Presence] in Urine by Screen method
0
8
0.00
0.00
0.0
1.5
—
—
—
0
0
(40768793) Breast Pathology biopsy report
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
(4094501)
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
(3021236) Streptolysin O Ab [Units/volume] in Serum or Plasma
0
5
0.00
0.00
0.0
1.0
—
86.4
—
0
5
(3042975) Streptococcus sp identified in Isolate by Organism specific culture
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
(3028271) Lactate [Moles/volume] in Capillary blood
0
5
0.00
0.00
0.0
1.4
—
2.2
—
0
5
(3026515) Parvovirus B19 IgM Ab [Units/volume] in Serum
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
(3044941) Cell count panel - Synovial fluid
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
(40759883) Oligoclonal Bands IgG [Presence] in Cerebral spinal fluid by Isoelectric focusing
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
(3014973) Borrelia burgdorferi IgM Ab [Units/volume] in Cerebral spinal fluid
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
(3024474) Albumin [Mass/volume] in Cerebral spinal fluid
0
5
0.00
0.00
0.0
1.0
—
202.0
—
0
5
(3005570) Glucose [Moles/volume] in Urine
0
5
0.00
0.00
0.0
5.0
—
—
—
0
0
(3019897) Erythrocyte distribution width [Ratio] by Automated count
0
5
0.00
0.00
0.0
1.0
—
14.2
—
0
5
Mortality – FinRegistry
↥Association
Association between endpoint E4_CYSTFIBRO_NAS and mortality.
Females
No dataMales
No dataMortality risk
Mortality risk for people of age
years, who have E4_CYSTFIBRO_NAS.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | No data |
| 5 | No data | No data |
| 10 | No data | No data |
| 15 | No data | No data |
| 20 | No data | No data |
Relationships between endpoints
↥Index endpoint: E4_CYSTFIBRO_NAS – Cystic fibrosis, other manifestations/unspecified
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
Extremity
rg [CI]
Extremity
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data